

The *in vitro* and *in vivo* characterization of ADCs (Antibody-Drug Conjugates) during early-stage R&D is critical to ensure the selection of efficacious and safe drug candidates. *In vitro* characterization includes the assessment of ADC internalization, stability, specificity, cytotoxic potency cytotoxicity, and antigen binding and developability before and after conjugation to understand the ADC's efficacy to its target and to elucidate any off-target effects. *In vivo* characterization, on the other hand, provides critical insights into pharmacokinetics, biodistribution, and toxicity profiles, which are indispensable for predicting how ADCs will perform within a living organism. WuXi Biologics offers comprehensive, one-stop *in vitro* and *in vivo* characterization services to assist our clients and enable them to discover the ideal ADC candidate to move into CMC development and on to clinical trials.


## ADC *in vitro* Characterization Platform

Comprehensive antibody screening and characterization assays throughout the lead identification and optimization process are provided. We also offer assay development services as required for your specific project needs.

### ADC *in vitro* characterization services include:

- Antigen-Antibody binding before and after conjugation
- Internalization analysis: Multiple methods
- Cytotoxicity and Bystander killing evaluation
- Serum/plasma stability studies

The following diagrams and case studies highlight our various capabilities:



## ADC *in vivo* characterization platform

Our highly-experienced scientists and experts provide the full-spectrum of *in vivo* characterization services including *in vivo* efficacy evaluation of therapeutic antibodies, ADCs and other large molecules for the treatment of tumors and inflammatory disease.


### Capabilities include:

- Comprehensive *in vivo* efficacy evaluation models and PK profiling methods
- Extensive capacity for PD and histological evaluation



## Comprehensive *In Vivo* Efficacy Evaluation Models and PK Profiling Methods


WuXi Biologics provides an extensive collection of tumor/mouse models for *in vivo* efficacy assessment of ADCs.



WuXi Biologics has established a variety of methods validated for consistency and accuracy, to detect total antibody, total ADC and free drug.


### Methods:

- LC-MS
- ELISA, MSD: Fc-Fc, Fc-Fab, Fc-Drug




## Extensive Capacity for PD and Histological Evaluation

WuXi Biologics provides high-quality PD evaluation services and has experts with years of experience utilizing FACS, ELISA, MSD and IVIS systems.



We offer comprehensive, high-quality pathology services utilizing advanced instruments.



## About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

The world's leading global single-source platform from concept to commercialization.

wuxibiologics.com | info@wuxibiologics.com

**WuXi Biologics**  
Global Solution Provider

**Learn more:**  
ADC *In Vitro*/*In Vivo*  
Characterization Services

